

NOV 02, 2023

OPEN BACCESS



DOI:

dx.doi.org/10.17504/protocol s.io.e6nvwjo5zlmk/v1

Protocol Citation: Vera A. Tang, Sean M Cook, Joanne Lannigan, Jennifer Jones, Joshua A Welsh 2023. Resource 7: rEV immunophenotyping. protocols.io

https://dx.doi.org/10.17504/protocols.io.e6nvwjo5zlmk/v1

License: This is an open access protocol distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

Created: Jan 30, 2023

Resource 7: rEV immunophenotyping



Sean M

Vera A. Tang¹, Cook², Joanne Lannigan³, Jennifer Jones², Joshua A Welsh⁴

¹University of Ottawa;

²Laboratory of Pathology, Translational Nanobiology Section, Centre for Cancer Research, National Institute of Health, National Institutes of Health;

³Flow Cytometry Support Services;

⁴Translataional Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health

Translational Nanobiology Section



Jennifer Jones

DISCLAIMER

This protocol summarizes key steps for a specific type of method, which is one of a collection of methods and assays used for EV analysis in the NCI Translational Nanobiology Section at the time of submission of this protocol. Appropriate use of this protocol requires careful, cohesive integration with other methods for EV production, isolation, and characterization.

Last Modified: Nov 02,

2023

PROTOCOL integer ID:

76114

Funders Acknowledgement:

NIH

Grant ID: ZIA BC011502

NIH

Grant ID: ZIA BC011503


NIH


Grant ID: 4UH3TR002881-03

ABSTRACT

Flow cytometry (FCM) is a common extracellular particles (EPs), including viruses and extracellular vesicles (EVs), characterization method. Frameworks such as MIFlowCyt-EV exist to provide reporting guidelines for metadata, controls, and data reporting. However, tools to optimize FCM for EP analysis in a systematic and quantitative way are lacking. Here, we demonstrate a cohesive set of methods and software tools that optimize FCM settings and facilitate cross-platform comparisons for EP studies. We introduce an automated small particle optimization (SPOT) pipeline to optimize FCM fluorescence and light scatter detector settings for EP analysis and leverage quantitative FCM (qFCM) as a tool to further enable FCM optimization of fluorophore panel selection, laser power, pulse statistics, and window extensions. Finally, we demonstrate the value of qFCM to facilitate standardized cross-platform comparisons, irrespective of instrument configuration, settings, and sensitivity in a cross-platform standardization study utilizing a commercially available EV reference material.

MATERIALS





3 Dilute the reconstituted rEVs 1 in 5 in PBS for staining* Take A 50 µL of the rEV stock and add



 \perp 200 μ L of PBS.

Note

The sample concentration chosen for staining should take into consideration the need to dilute the sample further after staining to reduce the concentration of free antibodies, since the samples will be acquired without a washing step to remove these antibodies as in the case of cells.

4 Prepare the antibody dilutions for a 2x staining concentration of each of the antibodies to be used in the antibody titration. See the example below for sample calculations prepared for a staining concentration of 2 µg/ml.

A	В	С	D	E	F
	AB stock concentration (µg/ml)	2x staining conc (µg/ml)	Stock volume for 2x staining conc (µL)	Total volume for 2x staining conc (µL)	Volume of PBS to be added (uL)
anti-Human CD81-PE	120	4	2	60	58
anti-Human CD81-APC	200	4	2	100	98
anti-Human CD81-PB	300	4	2	150	148

Sample calculations prepared for a staining concentration of 2 µg/ml. All Antibodies clones are 5A6.

5 Samples will now be prepared using the following plate map.

A	В	С	D	E	F	G	Н
	CD81 PE	CD81 APC	CD81 Pacific Blue	CD81 PE	CD81 APC	CD81 Pacific Blue	
	rEV	rEV	rEV	PBS	PBS	PBS	
0 μg/mL	A1	A2	A3	A4	A5	A6	
0.0625 μg/mL	B1	B2	B3	B4	B5	В6	

A	В	С	D	E	F	G	Н
0.125 μg/mL	C1	C2	C3	C4	C5	C6	
0.25 μg/mL	D1	D2	D3	D4	D5	D6	
0.5 μg/mL	E1	E2	E3	E4	E5	E6	
1 μg/mL	F1	F2	F3	F4	F5	F6	
2 μg/mL	G1	G2	G3	G4	G5	G6	QbSure Beads
	PBS	PBS	PBS	PBS	PBS	PBS	100 nm PS NIST- Traceable Beads

- 6 In a 96-well V-bottom plate, add $\boxed{\bot}$ 10 μ L 1:5 rEV solution to wells A1-A3
- 8 Add $\underline{\mathbb{Z}}$ 20 μL DPBS to wells A4-A6. These wells will serve as buffer only controls
- In the same 96-well V-bottom plate from 5 go to step #6, add 4 10 µL from the corresponding PE working solutions tube to wells B4-G4. Add 4 10 µL from the corresponding APC working solutions tube to wells B5-G5. Add 4 10 µL from the corresponding PB working solutions tube to wells B6-G6. These wells will serve as the DBPS+AB control wells.

30m

Using a separate 96-well V-bottom plate, add \square 199 μ L DPBS into wells A1-G6. Pipet \square 1 μ L from the incubation plate into the new plate in the same wells and reverse pipette to mix.

Note

Steps 11 and 12 will be repeated for the ON incubations as well to bring rEVs down to running concentration that doesn't swarm the instrument detectors.

- Add A 200 µL DPBS into wells A7-G7. These wells will help reduce sample carryover after each rEV+AB combination is acquired.
- Re-cover incubation plate and let incubate ON at RT to repeat measurements next day as directed in the following steps.
- Label as FACS tube as 'QbSure', and add Δ 500 μL DPBS. Vortex the QbSure beads for 5 sec and add 3 drops QbSure beads into FACS tube.

Cytometer Setup


- Setup cytometer to acquire at FCM_{PASS} output gains for both light scatter and fluorescent detectors as determined by the FCM_{PASS} detector optimization module outputs. For the Aurora, an optimal gain template is returned to import into the Spectraflo software.
- On the Cytek Aurora, set window extension to 0. On the CytoFLEX platform turn on 'High Acquisition Mode'.


Note

To set the window extension to 0 on the Cytek Aurora, navigate to the 'Lasers' tab under the sample acquisition settings and set the window extension to 0.

To change the acquisition mode on the CytoFLEX S, click on the 'Advanced' menu on the top-of-the-screen ribbon. Next click on 'Event Rate Settings' menu, change the acquisition mode to 'High', and press 'Ok'.

- Set the cytometer triggering threshold to the violet SSC parameter and run a DPBS control first to ensure the cytometer is clean and thresholds/event rates have remained unchanged. The background event rate should be ~1000 events/sec. All samples should be acquired with the lowest flow rate, typically ~10-15 µL min⁻¹.
- 19 Acquire all wells for at least 60 sec.
- In an open well, run the 100 nm polystyrene NIST beads at the same settings as the rEVs (diluted in DPBS to a concentration of 5E6 p/mL) until at least 10000 bead events have been acquired.
- In an open well, add 200 µL from the QbSure FACS tube and collect 10,000 bead events at the same settings as the rEVs.





QbSure beads gated on blue SSC-H and FSC-H on the Cytek Aurora and CytoFLEX S. The violet SSC settings remain unchanged. In order to limit .fcs file size, a FSC scatter trigger may be


used until 10000 QbSure bead events are acquired.

Note

You may need to adjust the B-SSC and FSC detector settings for the bead acquisition. Do not adjust fluorescence detector settings or high sensitivity SSC detector settings.

Assuming the QbSure beads were cross calibrated in the previous protocols, this allows for the calibration of the rEV fluorescent data into calibrated units.

If calibration of data into standard units is desired, the 100 nm polystyrene NIST bead and QbSure beads can be used to calibrate data by following the FCM_{PASS} experiment calibration protocols.



Don't forget to repeat the acquisition for the samples incubating ON.